Core Viewpoint - The Hong Kong IPO market is experiencing a surge in demand, with Guoen Technology Co., Ltd. (referred to as "Guoen") launching its H-share offering, indicating strong investor interest and confidence in the company's growth potential [1][4]. Group 1: IPO Details - Guoen's H-share offering consists of 30 million shares, with approximately 10% allocated for public sale in Hong Kong and 90% for international investors [1]. - The price range for the H-share issuance is set between HKD 34 and HKD 42, with the public offering portion exceeding HKD 3.3 billion and an oversubscription rate of nearly 30 times [1][4]. Group 2: Investor Confidence - The cornerstone investor lineup for Guoen's IPO includes prominent institutions such as Liguan Investment, SLD International, and Luminous Horizon, collectively planning to subscribe for approximately HKD 320 million of the offering [4][5]. - The backing from these institutional investors reflects a strong market perception of Guoen's long-term value and growth prospects [5]. Group 3: Company Strengths - Guoen is recognized as the second-largest producer of organic polymer modified materials and organic polymer composite materials in China, and the largest producer of polystyrene by capacity [7]. - The company serves major clients in the home appliance, automotive, and new energy sectors, including Hisense, Midea, BYD, and CATL [7]. - In the health sector, Guoen controls Dongbao Biological, covering the entire industrial chain from gelatin raw materials to hollow capsules, ranking second in bone gelatin production and second among domestic brands in hollow capsule production in China [7]. Group 4: Fund Utilization - Guoen plans to allocate approximately 50% of the raised funds to establish a new production base in Thailand to expand capacity, while 35% will be used to enhance the production capacity of its Yixing facility [9]. - This strategic expansion aligns with the trend of downstream industries, such as home appliances and automotive, moving overseas, thereby opening new growth opportunities for the company [9].

Core Viewpoint - The company, Guoen Technology (02768), is set to launch an IPO from January 27 to January 30, 2026, offering 30 million shares globally, with a price range of HKD 34.00 to HKD 42.00 per share, and aims to raise approximately HKD 1.058 billion for capacity expansion and operational purposes [1][5]. Group 1: Company Overview - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [1]. - The company focuses on R&D, production, and sales of industrial and commercial products, catering to manufacturers in downstream sectors such as automotive, new energy, and home appliances [1]. Group 2: Chemical Industry Segment - In the chemical industry, the company has a comprehensive product range that includes upstream green petrochemical materials and midstream organic polymer modified materials [2]. - The company is the second-largest player in China's organic polymer modified materials and organic polymer composite materials market, with a market share of 2.5% as of 2024 [2]. - It is also the largest producer of polystyrene in China by capacity as of 2024 [2]. Group 3: Health Industry Segment - In the health sector, the company focuses on the natural collagen industry and has established a vertically integrated product line from collagen to end products [3]. - The company ranks second in China's bone gelatin production by output and is the leading domestic brand in this category as of 2024 [3]. - It is also the second-largest domestic brand in the hollow capsule production market by output as of 2024 [3]. Group 4: Investment and Fund Allocation - The company has secured cornerstone investment agreements totaling approximately HKD 320 million, with key investors including Liguang Investment and others [4]. - The net proceeds from the IPO are expected to be around HKD 1.058 billion, with allocations of 50% for expanding production capacity in Thailand, 35% for capacity expansion in China, 10% for investments in Hong Kong, and 5% for operational funds [5].

Core Viewpoint - The company, Guo'en Technology, is set to launch an IPO from January 27 to January 30, 2026, offering 30 million shares globally, with a price range of HKD 34.00 to HKD 42.00 per share, and aims to raise approximately HKD 1.058 billion for expansion and operational purposes [1][5]. Group 1: Company Overview - Guo'en Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [1]. - The company focuses on R&D, production, and sales of industrial and commercial products, catering to manufacturers in downstream sectors such as automotive, new energy, and home appliances [1]. Group 2: Chemical Industry Segment - In the chemical industry, the company has a comprehensive product range that includes upstream green petrochemical materials and midstream organic polymer modified materials [2]. - The company is the second-largest player in China's organic polymer modified materials and organic polymer composite materials market, with a market share of 2.5% as of 2024 [2]. - It is also the largest producer of polystyrene in China by production capacity as of 2024 [2]. Group 3: Health Industry Segment - In the health sector, the company focuses on the natural collagen industry, with a vertical integration strategy that spans from collagen to end products [3]. - The company is the second-largest producer of bone gelatin in China by output and the largest domestic brand in this category as of 2024 [3]. - It ranks as the second-largest domestic brand in the hollow capsule production sector in China by output as of 2024 [3]. Group 4: Investment and Fund Allocation - The company has secured cornerstone investment agreements totaling approximately HKD 320 million, with investors including several financial institutions [4]. - The net proceeds from the IPO are expected to be around HKD 1.058 billion, with allocations planned for expanding production capacity in Thailand (50%), China (35%), and investments in Hong Kong (10%) [5].

Company Overview - Guoen Co., Ltd. (002768) is undergoing a listing hearing on the Hong Kong Stock Exchange, sponsored exclusively by China Merchants Securities International. The company operates in two main segments: Advanced Chemicals (Chemical New Materials) and Health Products (Gelatin, Collagen, and related upstream and downstream products) [1] Advanced Chemicals Segment - The Advanced Chemicals segment focuses on the chemical new materials industry, offering products such as green petrochemical materials (e.g., aromatic olefins, styrene, polystyrene) and organic polymer modified materials and composites. These products serve downstream industries including automotive, new energy, and home appliances [1] - According to Frost & Sullivan, Guoen Co., Ltd. is the second largest company in China for organic polymer modified materials and organic polymer composites by sales revenue in 2024, holding a market share of 2.5%. It is also the largest producer of polystyrene in China by production capacity in 2024 [1] Health Products Segment - The Health Products segment focuses on the natural collagen industry, developing collagen peptide derivatives and end products through its subsidiary Dongbao Biological (300239). The primary customers are medical and pharmaceutical manufacturers [1] - Based on Frost & Sullivan's data, Guoen Co., Ltd. ranks as the second largest producer of bone gelatin in China by production volume in 2024, and it is the largest domestic brand in this category. Additionally, it is the second largest domestic brand in the hollow capsule production sector in China, according to 2024 production volume estimates [1] Market Outlook - The market for organic polymer modified materials and organic polymer composites in China is projected to grow from RMB 544.8 billion in 2024 to RMB 1,037.5 billion by 2029, reflecting a compound annual growth rate (CAGR) of 14.1% [2]

Core Viewpoint - On May 26, 2025, Guoen Technology Co., Ltd. announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international capital operations and accelerate the establishment of a dual circulation pattern in the domestic and international markets [1][5]. Group 1: H-Share Issuance and Listing - The company plans to issue H-shares not exceeding 15% of the total share capital post-issuance, with proceeds allocated for establishing a Hong Kong regional headquarters, R&D investments, capacity expansion, strategic investments, and operational funding [1][5]. - The issuance and listing are subject to shareholder approval and regulatory approvals [1]. Group 2: Management Changes - On the same day, the company announced the resignation of two board members, Zhang Shide and Liu Shuyuan, due to personal reasons, with no impact on the board's legal quorum [1][2]. Group 3: Company Overview and Financial Performance - Founded in December 2000 and listed in June 2015, Guoen Group has developed a diversified portfolio in green petrochemicals, organic polymers, and health-related products, among others [4]. - In 2024, the company reported revenue of 19.219 billion yuan, a 10.21% increase from the previous year, and a net profit of 676 million yuan, up 45.18% year-on-year [4]. - The chemical industry segment generated 17.369 billion yuan, accounting for 90.38% of total revenue, while the health industry segment saw a decline in revenue [4]. Group 4: Recent Financial Results - In Q1 2025, the company reported revenue of 4.412 billion yuan, a slight decrease of 0.23%, and a net profit of 111 million yuan, down 9.79% year-on-year [5]. - As of March 31, 2025, total assets were 18.971 billion yuan, a 23.71% increase year-on-year, while total liabilities rose by 34.64% to 11.866 billion yuan [5].

Group 1 - Company plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to advance its global strategy and enhance its international capital operation platform [1] - The company aims to consider the interests of existing shareholders and the conditions of domestic and international capital markets when determining the timing and window for the issuance [1] - As of now, the company has developed a vertically integrated industrial cluster in new chemical materials, including green petrochemicals and biodegradable materials [1] Group 2 - In the large chemical industry, the company focuses on creating three main business engines: green petrochemical materials, organic polymer modified materials, and organic polymer composite materials [2] - The subsidiary, Dongbao Biological, specializes in the research, production, and sales of gelatin and collagen products, providing comprehensive solutions for downstream users [2] - The company operates both B2B and B2C business models, with B2B products including gelatin and collagen used in various sectors such as healthcare and beauty [2] Group 3 - In 2024, the company will focus on its main business, leveraging its vertical integration in the large chemical and health industries to drive growth [3] - The company expects to achieve a revenue of 19.22 billion yuan, a year-on-year increase of 10.21%, and a net profit of 676 million yuan, a year-on-year increase of 45.18% [3]